Dengue virus infection is more and more acknowledged as one of the world's major escalating problems. Dengue is prevalent in most tropical and subtropical countries. To solve this problem, pharmacists need to understand the epidemiology, risk factors, clinical spectrum, diagnosis, management, prevention, and novel avenues of dengue.
Introduction
Dengue is the most frequent origin of arboviral infection. Four dengue (DEN) virus serotypes are, known as DEN-1, DEN-2, DEN-3, and DEN-4. They fit into the genus Flavivirus, family unit Flaviviridae having approximately 70 viruses [1] . Now, the disease is more widespread than at any other time, and its dominance is estimated to augment. The factors are complex and not fully understood, responsible for the dramatic reappearance of epidemic dengue and dengue hemorrhagic fever (DHF), correspondingly, as a universal community health problem in the past 17 years. Though, the recurrence appears to be directly related with demographic and communal changes more than the past 50 years [2] - [5] . Two major factors have been the recorded global population growth and the associated unplanned and uncontrolled urbanization, especially in tropical developing countries. Ideal conditions for increased transmission of mosquito-borne diseases in tropical urban centers have produced by the imperfect housing, crowding, and deterioration in water, open drain, and waste management systems allied with spontaneous urbanization.
Lack of effective mosquito control is a third major factor in areas where dengue is widespread [2] [4] [5] . Space spraying with insecticides to kill adult mosquitoes has been the most emphasized factor during the past 25 years; this has not been successful [7] and, in fact, has been adverse to prevention and control efforts by giving the general public of the society and government officials a "false sense of security". Enlarged air travel is a fourth factor responsible for the global appearance of dengue and DHF, which provides the perfect mechanism for the transfer of dengue and other urban pathogens between population centers of the world [2] - [5] . Decay in public health infrastructures in most countries in the past 30 years has been considered a fifth factor that has contributed to the reappearance of pandemic dengue. A critical shortage of trained specialists who understand and can develop effective prevention and control programs for vector-borne diseases has created by lack of funds. Concurrent with this has been a revised in public health policy that positioned importance on disaster response to epidemics by using high-technology mosquito control methods rather than on preventing those epidemics by using larval source decline through ecological sanitation, the only method that has been shown to be successful [5] .
In short, lack of resources for vector-borne infectious disease prevention and control, demographic and communal changes, and changes in public health policy have all contributed to amplifying happening dengue activity, the expansion of hyperendemicity, and the appearance of epidemic DHF.
Dengue hemorrhagic fever (DHF) is a critical sign of dengue, which is more frequent after a secondary infection with dengue virus. Cost effective vaccine and drugs are considered necessary for the prevention and control of dengue.
Dengue Case Classification
Alteration in the dengue epidemiology escorts to problems with the use of the presented WHO classification. Symptomatic dengue virus infections were grouped into three categories: undifferentiated fever, dengue fever (DF) and dengue hemorrhagic fever (DHF). DHF had more classified into four severity grades, with grades III and IV being defined as dengue shock syndrome (DSS) [8] . Many problems have been reported with the use of this classification [9] - [11] , which were summarized in a systematic literature review [12] . Problems in applying the criteria for DHF in the clinical situation, jointly with the increase in clinically severe dengue cases which did not accomplish the strict criteria of DHF, led to the request for the classification to be reconsidered. Presently the classification into DF/DHF/DSS continues to be extensively used [9] . Suggested dengue case classification and levels of severity ( Table 1 ) has a high potential for being of convenient use in the clinicians' decision as to where and how intensively the patient should be observed and treated, in more consistent exposure in the national and international surveillance system, and as an endpoint measure in dengue vaccine and drug trials.
Diagnosis of Dengue
For clinical care efficient and accurate diagnosis of dengue is of primary importance (i.e. Early recognition of severe cases, case authentication and differential diagnosis with other infectious diseases), surveillance actions, outbreak control, pathogenesis, academic research, vaccine development, and clinical trials. • live in/travel to dengue endemic area.
• Fever and 2 of the following criteria:
• Nausea, vomiting
• Rash
• Aches and pains
• Tourniquet test + ve
• Leukopenia
• Any warning sign Laboratory-confirmed dengue (Important when no sign of plasma leakage)
• Abdominal pain or tenderness
• Persistent vomiting
• Clinical fluid accumulation
• Mucosal bleeding
• Lethargy, restlessness
• Liver enlargement > 2 cm
• Laboratory: ↑ in HCT
• Concurrent with rapid ↓ in platelet count * (Requiring strict observation and medical intervention)
Severe plasma leakage leading to:
• Shock (DSS)
• Fluid accumulation with respiratory distress
Severe bleeding
As evaluated by clinician Severe organ involvement
• Liver: AST/ALT > 1000
• CNS: Impaired consciousness
• Heart and other organs as well
Clinical Management and Delivery of Clinical Services
Dengue virus causes a systemic and dynamic disease which has a wide clinical spectrum that includes both severe and non-severe clinical features [13] . The illness begins abruptly and is followed by the three phases-febrile, critical and recovery (Table 2 ) after the incubation period. For an infection that is complex in its manifestations, management is relatively simple, economical and very effective in saving lives so long as right and well-timed interventions are instituted. The key is early identification and understanding of the clinical troubles during the different phases of the illness, leading to a rational approach to case management and an excellent clinical result. Pharmacist should ensure stepwise approach to the clinical management of dengue given in Table 3 and Table 4 .
Severe Dengue
Severe dengue is defined by one or more of the following: 1) Plasma leakage that may lead to shock (dengue shock) and/or fluid accumulation, with or without respiratory distress, and/or 2) Severe bleeding 3) Severe organ impairment If the patient is from an area of dengue risk presenting with fever of 2 -7 days plus any of the following manifestations severe dengue should be considered: 1) Plasma leakage supported by such as: high or progressively rising haematocrit; pleural effusions or ascites; circulatory compromise or shock (tachycardia, cold and clammy extremities, capillary refill time greater than three seconds, weak or untraceable pulse, narrow pulse pressure or, in late shock, recordable blood pressure).
2) Significant bleeding 3) Altered level of consciousness (lethargy or restlessness, coma, convulsions) 4) Severe gastrointestinal involvement (constant vomiting, growing or intense abdominal pain, jaundice 5) Severe organ destruction (acute liver failure, acute renal failure encephalopathy or encephalitis, or other unusual manifestations, cardiomyopathy) or other curious manifestations.
Prevention and Control of Dengue
For effective programmed management important activities are regular monitoring of the delivery of dengue prevention and control services and evaluation of the impact of interventions. Appropriate indicators should be A stepwise approach to the management of dengue
Step I. Overall assessment I.1 History, including information on symptoms, past medical and family history I.2 Physical examination, including full physical and mental assessment I.3 Investigation, including routine laboratory and dengue-specific laboratory
Step II. Diagnosis II.1 Assessment of disease phase and severity
Step III. Management III. 
Rational Practices to Treat Dengue Patient
The pharmacist should play a key role in good clinical practices to ensure rational treatment to the dengue patient as given in Table 5 .
Novel Avenues
Vector control and personal protection from the bites of infected mosquitoes are currently possible key prevention of dengue. But, the development of drugs and vaccines has the potential to revolutionize this. For an anti-dengue drug and vaccines, there are various requirements. Oral route of administration, frequency of dosing of once per day, stability in the face of heat and humidity, a long shelf-life, and small/reasonable cost of goods and ease of formulation to permit a reasonably priced product should be included in the minimal target drug profile [14] . The drug must be active against all serotypes, reduce symptoms, and reduce the incidence of severe disease, with respect to clinical efficacy. In addition, a safe and sound drug should be evaluated to make use of prophylactic as well as pediatrics after suitable trials.
